Volumen: 19 # Number : 1
Publication Date : Enero - Abril Year: 2015
Authors: Miroli M. Augusto
Abstract: Obinutuzumab is a type II anti-CD20 humanized
monoclonal antibody with modified FC fragment
with increase antibody-dependent cellular cytotoxicity
and direct cell death in comparison with Rituximab.
It was recently FDA approved for its use in
treatment-naive unfit CLL patients in combination
with Clorambucil. Infution related reactions and
neutropenia are the most common adverse events.
Key words: Obinutuzumab, CLL, Anti CD20 Monoclonal
antibody.
Pages :
|
